Gaucher is a closed pool. Low incidence means new diagnoses barely expand the base, so this is a share-transfer market rather than a growth market.
Several agents are approved across enzyme replacement and substrate reduction, and with little incident inflow they are allocating a largely fixed number of patients between them. That changes what a forecast is: the exercise is share transfer within a stable prevalent pool, not participation in growth. Assumptions imported from a growing market will not hold.
Metaboliser status gates oral substrate reduction therapy. Eligibility for the oral agent depends on a genetic metaboliser phenotype, with one group excluded outright - and that excluded group is meaningfully represented in the founder population in which the disease is most concentrated. The genotype filter has to be built into the sizing rather than applied as a footnote, because it removes a defined share of the apparent opportunity.
Lifetime enzyme replacement economics are what a disruptor competes against. Recurring therapy bills a substantial annual sum for life, so a one-time therapy competes on cumulative rather than annual cost, and the comparison depends entirely on the time horizon chosen. Gene therapy in development would reset that arithmetic, and the value case for any current agent should be built knowing the comparison is coming.
AXLRx Gaucher reports map the approved agents by mechanism and eligibility, build the metaboliser filter into the sizing, and model the closed-pool share transfer against the lifetime cost the market is currently built on.
Gaucher type 1 epidemiology, the Ashkenazi Jewish founder burden, GBA1 genotype–phenotype, and the 20-fold Parkinson's risk.
Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.
IV enzyme replacement buy-and-bill under Part B vs oral SRT under Part D, the CYP2D6 PA gate, and generic miglustat.
Five approved Type 1 Gaucher therapies treat the body, not the brain. A genotype gate locks a meaningful share of the highest-prevalence population out of the only oral option, and a Phase 3 gene therapy trial is now racing to close that gap.
Three IV enzyme replacement brands run ~$300,000/year with no generic rival, so preferred-ERT designation is the real pricing lever. Eliglustat's CYP2D6 gate and generic miglustat's trial-first rule complete the picture.
6,000 US Type 1 Gaucher patients size a market near $1.8 billion at ERT pricing. That MedlinePlus-sourced population sits inside a genetic sub-segment where Ashkenazi carrier frequency runs 1 in 12-15, against a general-population disease frequency of just 0.70-1.75 per 100,000.
Gaucher disease is an autosomal recessive GBA1 lysosomal storage disorder, and more than 90% of patients have non-neuronopathic type 1. General-population prevalence runs 0.70 to 1.75 per 100,000, but the Ashkenazi Jewish founder variant N370S lifts disease frequency to roughly 1 in 500 to 1,000 and carrier frequency to about 1 in 12 to 15. NIH MedlinePlus estimates roughly 6,000 US type 1 patients. Neuronopathic types 2 and 3, tied to L444P homozygosity, are far rarer.
Confirmation rests on two tests. A low acid beta-glucosidase (glucocerebrosidase) enzyme assay establishes the enzyme deficiency, and GBA1 genetic testing identifies the biallelic variants that define disease subtype, N370S predicting type 1, L444P homozygosity predicting neuronopathic types 2 and 3. Genotype also guides therapy, because eliglustat eligibility requires a separate CYP2D6 metabolizer test. Because splenomegaly, thrombocytopenia and bone pain are nonspecific, identifying and confirming latent patients is the strategic problem, not the assay itself, which is definitive once ordered.
Five FDA-approved therapies split across two mechanisms. Three intravenous enzyme replacement therapies replace deficient acid beta-glucosidase: imiglucerase (Cerezyme, Sanofi, 1994), velaglucerase alfa (VPRIV, Takeda, 2010) and taliglucerase alfa (Elelyso, Pfizer, 2012). Two oral substrate reduction therapies inhibit glucosylceramide synthase to lower substrate load: eliglustat (Cerdelga, Sanofi, 2014) and miglustat (Zavesca, 2003, now generic). Eliglustat is the only first-line oral option, restricted to CYP2D6 extensive, intermediate or poor metabolizers, and in ENGAGE it cut spleen volume 30% versus placebo.
Start from the prevalent treated base, not incident diagnoses, because the roughly 6,000 US type 1 patients are mostly already controlled on intravenous imiglucerase, velaglucerase alfa or taliglucerase alfa. Size the switchable pool by intersecting three filters: stable disease control, CYP2D6-eligible genotype and sensitivity to lifelong infusion burden. Model the conversion rate from Part B buy-and-bill ERT to Part D oral eliglustat or a next-generation SRT, geography by geography. The forecast is share-of-switch, not share-of-growth, so the funnel from identified patient to switched patient is the strategy, and share-of-voice against three entrenched ERTs matters less than switch velocity.
Eliglustat is approved only for CYP2D6 extensive, intermediate and poor metabolizers, and ultrarapid metabolizers are excluded, a group representing 8.8% of Ashkenazi Jewish patients, the very founder population that enriches the disease. A genotype test therefore partitions the addressable oral pool at the front of the funnel, so the forecast must model a test-and-treat sequence rather than a flat conversion. Segment the prevalent base into genotyped subpopulations, apply the eligibility haircut, then size only the qualifying pool. This is why oral SRT sizing is a genotype-segmentation exercise, not a simple share assumption, and why the genotype lever precedes any promotional spend.
Treat it as a closed-pool share transfer among the five approved agents rather than a growth market, because low incidence means new diagnoses barely expand the base. The exercise is allocating a fixed pool across mechanism and route, then testing how switching redistributes it over time. At roughly $300,000 per year the ERT-priced total addressable market nears $1.8 billion, and at eliglustat's $310,250 WAC it nears $1.86 billion. Since no generic ERT exists, payers lever preferred-versus-non-preferred designation rather than price, so the model tracks formulary position and switch velocity, not volume expansion. Growth comes from converting the treated base, not from finding net-new patients.
Recurring enzyme replacement bills roughly $300,000 per patient per year for life, so a one-time therapy competes on cumulative rather than annual cost. Spur Therapeutics' avigbagene parvec (FLT201), a liver-directed AAV therapy, let Phase 1/2 patients discontinue standard ERT or SRT for roughly two years after a single infusion and entered pivotal Phase 3 GALILEO-3 (about 45 adults) in July 2026. Model a one-time price against the discounted lifetime ERT stream to find the breakeven a payer will defend, then stress the switchable pool against durability risk. Sanofi's CNS-penetrant venglustat is filed for type 3 only, leaving type 1 as the gene-therapy battleground.
Each answer is drawn from a commissioned AXLRx report, a disease-landscape read on epidemiology and the identification funnel, a competitive-intelligence map of the five approved agents by mechanism and route, a payer-and-access view of Part B versus Part D routing and prior-authorization gates, a pricing-strategy model of preferred-ERT and switch levers, a market-sizing model translating the roughly 6,000-patient pool into ERT-versus-SRT TAM, and a launch-readiness assessment of the gene-therapy threat. AXLRx builds each across US, UK and GCC geographies from primary FDA, payer-policy and trial-registry sources.